Dear BioFITers,

Two new experts joined BioFIT line-up this week!

• Tzachy Tal, Director of Business Development at the Technion’s Technology Transfer Office in Haifa will speak in Track 2’s session “To spin or not to spin”, dedicated to key issues in licensing and tech transfer

and

• Dr Iain Thomas, Head of Life Sciences, Cambridge Enterprise, UK, probationally agreed to speak his mind in the session “Committed to the VC business: why and how universities take part in new venture funds?”, featured in BioFIT Track 3, dedicated to financing early-stage innovation

We are looking forward to attending the session and we hope to meet you there

BioFIT team will be in Lyon (France) to attend BioVision on April 13th & 14th.

BioVision is an annual meeting, which brings together international decision makers and innovation holders from the academic, private, policy-making and civil society sectors to debate, find partnerships and invest.

Beyond the foresight, BioVision‘s ambition is to facilitate collaboration between different actors, innovation and ultimately access to knowledge and solutions for the general public.

Take advantage of that perfect opening to get an extensive overview of BioFIT activities, or just have a chat with our team 😉 !

Dear BioFITers,

You were waiting, you were looking forward to it and finally here they are!

We have the pleasure to introduce BioFIT 2016 first speakers as this year we are welcoming:

• Kai Simons, Research Group Leader and Director Emeritus of the Max Planck Institute of Molecular Cell Biology and Genetics, and CEO of Lipotype, a spin-out focusing on translating lipidomics and lipid analysis to clinical and industrial applications

and

• Stefan Nilsson, CEO of Lipigon Pharmaceuticals, developing innovative first-in-class drugs aiming at treating Dyslipidemia patients

Messrs Simons and Nilsson will share their expertise in Track 2, dedicated to key issues in licensing and tech transfer. We will have the pleasure to hear them speak their minds in the session

“What is the best background for an academic spin-off CEO: science or industry?”

We are looking forward to attending the session and we hope to meet you there

The 3 activities of the BioFIT Presentation Sessions give young entrepreneurs, researchers and tech transfer professionals the opportunity to present their projects and find partners who share their vision.

• Are you already or thinking about creating an innovative academic spin-off company and do you have a business plan to present?

Please apply for the Business Plan Slams and get the opportunity to present your business plan, raise awareness among pharmas, biotechs, TTOs, investors and media, and in addition receive valuable feedback and advices from an expert jury

---

Please apply for the Licensing Opportunities Presentations and get the opportunity to present your technology and raise awareness among pharmas, biotechs, TTOs, investors and media.

The BioFIT Licensing Opportunities Presentations are organised in partnership with TechnoMarket

BioFIT team and NHL Cluster will be in Stockholm (Sweden) to attend

BIO-Europe Spring on March 4^th to 6^th.

BIO-Europe Spring continues this year the tradition of providing life science companies with high caliber partnering opportunities.That is everything needed to enable delegates to efficiently identify, meet and get partnerships started with companies across the life science value chain, but most of all, a perfect occasion to come and meet us !

Take advantage of that perfect opening to get an extensive overview of BioFIT activities,or just have a chat with our team 😉 !

BioFIT team will be pleased to attend Forum LABO & BIOTECH

on March 30th & 31th in Lyon, France

The Forum LABO & BIOTECH is the exhibition of laboratory materials and services suppliers. This event gathers researchers, engineers, scientists, buyers, and decision makers in all sectors (academic research, R&D, analysis and testing in agri-foods, the environment, chemicals, pharmaceuticals, biotechnology, healthcare, energy…)

With around 150 exhibitors, Forum LABO & BIOTECH is the right place to identify new partners but it’s also the perfect occasion to come and meet us! Take advantage of that perfect opening to get an extensive overview of BioFIT activities, or just have a chat with our team 😉

After the BioFIT Steering Committee meeting last month and the interesting exchanges that followed, this year’s preliminary topics have finally been decided. Focusing on entrepreneurship in Life Sciences, this year’s programme includes:

• Lessons learned: Do’s & don’ts from seasoned entrepreneurs
• What is the best background for an academic spin-off CEO: science or industry?
• How can industry and investor incubating models accelerate research translation?
• Are universities a short-term or long term partner for spin-offs?

View the conference programme

Would you like to:

• Share your experience, opinions and knowledge with our audience?
• Present your ideas with our panel?

Apply to be a BioFIT speaker! Contact us

Roche signs a €900M deal with Blueprint Medicines

Roche (Switzerland), leader in cancer therapies, has been redirecting its efforts towards immuno-oncology and has picked 5 candidates from Blueprint Medicines (Boston, US) to complement its leading oncology pipeline.
Blueprint Medicines will receive €40M upfront to collaborate on the development of 5 of its preclinical candidates. Depending on how these small molecule therapies perform in trials, Blueprint could be aiming at over €850M in milestones and licenses.

Source : La Biotech.eu 

AstraZeneca and Genentech put pen on paper and bankroll to finance PatientsLikeMe study on lung cancer

AstraZeneca and Genentech (a member of the Roche Group) have agreed to finance a study of lung cancer patients that will analyze PatientsLikeMe’s patient-reported outcomes alongside traditional forms of data. The project is designed to assess the value of giving researchers a broader overview of factors that can affect health outcomes.

Source : FierceBiotechIT

Cellectis and MabQuest announce immunotherapy partnership

Cellectis (France) and MabQuest announced that they have entered into a research collaboration and license agreement pertaining to the development of a new class of monoclonal antibodies targeting PD-1. These anti-PD-1 mAbs have potential uses for multiple indications in immunotherapy, including notably treatments for a variety of cancers.

Source : BusinessWire

Johnson & Johnson Innovation launches JLINX: A new company incubation model 

Located at the Janssen Campus in Belgium, JLINX will offer scientists and entrepreneurs access to venture funding, state-of-the-art facilities and R&D expertise. JLINX is designed to accelerate early-stage transformative innovation, including an emphasis on the human microbiome as well as broader life-science research.

Source : BusinessWire

We are honored to count among our Supporters for BioFIT 2016: Asebio, Atlanpole Biotherapies, BIA, Biocat, Bionow, BioPartner, Danish Diabetes Academy, Innoget, MediWales, One Nucleus…

Discover the 2016 Supporters here.

As these organizations, become a Supporter of BioFIT and:

• Increase your visibility among 1,300 Life Sciences leading actors
• Get a free pass to attend the event
• Offer your members an incredible 25% discount to attend the event
• …

Contact us to discover all the other benefits!

It’s time to sign up!

Early Bird

The arrival of spring season reminds us that the Early Bird is still running! It’s now time to sign up and benefit from 20% off on BioFIT regular registration fees.

Register now and enjoy the Early Bird offer!

Boost your visibility

With a limited number of stands, do not miss the opportunity to enhance your visibility at an international scale and get identified as a key innovative actor in Life Sciences.

Book your booth now and benefit from the best location in BioFIT exhibition area!